Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration

Part of paid clinical trials in Mountain View, California.

Sponsor
Southern California Desert Retina Consultants, MC
Study ID
NCT02140151
Phase
PHASE1/PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This study will determine whether quarterly injections of Ranibizumab may prevent eyes with dry age-related macular degeneration from progressing to wet age-related macular degeneration (AMD).

Key Dates

First listed
May 16, 2014
Start date
Sep 17, 2014
Status verified
Aug 2022
Primary completion
Jul 9, 2020
Completion
Jul 9, 2020

Study Design

Enrollment
108 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION

Arms

  • No Intervention: Sham
    Sham Injection
  • Active Comparator: Quarterly Ranibizumab 0.5mg
    Quarterly intravitreal injection of 0.5mg ranibizumab

Primary Outcome Measure

Development of exudative AMD [ Time Frame: 2 years ]

Locations (4)

FacilityCityStateZIPSite coordinators
Northern California Retina Vitreous AssociatesMountain ViewCalifornia94040-
Southern California Desert Retina ConsultantsPalm DesertCalifornia92211-
Elman RetinaBaltimoreMaryland21237-
Black Hills Regional Eye InstituteRapid CitySouth Dakota57701-

Find similar trials in Mountain View, CA

By condition
Age-related macular degeneration
By specialty
OphthalmologyRetina
By research site
Northern California Retina Vitreous Associates· Mountain View, CASouthern California Desert Retina Consultants· Palm Desert, CAElman Retina· Baltimore, MDBlack Hills Regional Eye Institute· Rapid City, SD

Related Studies